Vivek Ramaswamy, JPM20 (Credit: Jeff Rumans)
Vivek Ramaswamy's LNP delivery tech play Genevant scores $600M licensing deal from Takeda for nucleic acid therapies
With mRNA vaccines in high demand and new RNA therapeutics crowding onto the market, the demand for lipid nanoparticles has never been higher. Now, one of serial entrepreneur Vivek Ramaswamy’s Vant outfits has scored a big deal with Takeda to develop LNP-delivered liver drugs.
The Japanese drugmaker will earmark $600 million for a licensing deal with Genevant, an LNP delivery tech outfit, to develop nucleic acid therapies for liver fibrosis, the companies said Monday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters